期刊文献+

超顺磁氧化铁纳米微粒在HER-2阳性乳腺癌模型MRI和荧光成像中的应用 被引量:3

Application of superparamagnetic iron oxide nanoparticles in MRI and fluorescence imaging of HER-2 positive breast cancer model
下载PDF
导出
摘要 目的分析超顺磁氧化铁纳米微粒(SPIONs)在人表皮生长因子受体2(HER-2)阳性乳腺癌模型磁共振成像(MRI)和荧光成像中的应用。方法建立纳米探针,对其表征进行检测。制备乳腺癌小鼠模型,采用纳米探针于小鼠尾静脉注射,采用荧光成像和MRI判断纳米颗粒能否聚集于乳腺癌病灶部位。分别设置对照组、A组(应用四氧化三铁-免疫球蛋白G-吲哚菁绿)、B组(应用曲妥珠单抗+四氧化三铁-曲妥珠单抗-吲哚菁绿)、C组(应用四氧化三铁-曲妥珠单抗-吲哚菁绿)。检测纳米颗粒表征,给予小鼠活体MRI和活体荧光成像检查。结果本实验通过建立SPIONs,纳米颗粒平均粒径为(25.89±3.63)nm。偶联后的纳米颗粒于828处存在明显吸收峰,与荧光染料吲哚菁绿的荧光发射波长相同。纳米颗粒弛豫率较高,达107.67 nM^-1·s^-1。纳米颗粒溶液在近红外激光持续照射后的温度最高达57.85℃。采用纳米探针于小鼠尾静脉注射1 d后,活体MRI癌灶部位T 2信号最低。C组小鼠癌灶部位△T 2值为(30.68±5.14)ms,较对照组(3.13±0.98)ms、A组(4.52±1.15)ms、B组(12.14±2.25)ms显著升高(P<0.05);B组小鼠癌灶部位△T2值较对照组和A组显著升高(P<0.05)。活体荧光成像可见纳米颗粒于小鼠癌灶组织和腹腔脏器出现一过性浓聚,且经膀胱进行排泄,1d后于癌灶部位出现明显聚集。结论构建四氧化三铁-曲妥珠单抗-吲哚菁绿的SPIONs纳米探针可能是HER-2阳性乳腺癌MRI和荧光成像的一种潜在显像剂。 Objective To analyze the application of superparamagnetic iron oxide nanoparticles(SPIONs)in magnetic resonance imaging(MRI)and fluorescence imaging of human epidermal growth factor receptor 2(HER-2)positive breast cancer model.Methods Nano-probe was established and its characterization was detected.Breast cancer mouse model was prepared,and the tail vein of mice was injected with nano-probe.Fluorescence imaging and MRI were used to determine whether the nanoparticles could accumulate in the breast cancer lesion.Control group,group A(using triferrotetraoxy-immunoglobulin G-indocyanine green),group B(using trastuzumab+triferrotetraoxy-trastuzumab-indocyanine green),and group C(using triferrotetraox-trastuzumab-indocyanine green)were set respectively.Nanoparticle characterization was examined and live MRI and in vivo fluorescence imaging were performed in mice.Results The average particle size of SPIONs was(25.89±3.63)nm.The fluorescence emission wave length of indocyanine green was the same as that of indocyanine green.The relaxation rate of nanoparticles was higher,reaching 107.67 nM-1·s-1.Nanoparticles solution after the near-infrared laser light has the highest temperature of 57.85℃.After 1 d of intravenous injection of nano-probe into the tail vein of mice,the T 2 signal at the tumor focus of MRI in vivo was the lowest.The T 2 value(30.68±5.14)ms in the C group was significantly higher than that in the control group(3.13±0.98)ms,group A(4.52±1.15)ms,and group B(12.14±2.25)ms(P<0.05).T 2 value in cancer site of group B was significantly higher than that in control group and group A(P<0.05).In vivo fluorescence imaging showed transient concentration of nanoparticles in the tumor tissue and abdominal organs of mice,which were excreted through the bladder,and obvious aggregation in the tumor site 1 day later.Conclusion The SPIONs nano-probe may be a potential imaging agent for MRI and fluorescence imaging of HER-2 positive breast cancer.
作者 郭宝琴 刘蓉 吴党洁 GUO Bao-qin;LIU Rong;WU Dang-jie(Magnetic Resonance Chamber,The Second Hospital of Yulin,Yulin Shaanxi 719000,China;Department of Ultrasound,Air Force Military Medical University First Affiliated Hospital Xijing Hospital,Xi'an Shaanxi 710032,China)
出处 《临床和实验医学杂志》 2019年第22期2359-2362,共4页 Journal of Clinical and Experimental Medicine
基金 陕西省卫生计生科研基金项目(编号:2016D098)
关键词 小鼠 乳腺癌 荧光成像 磁共振成像 超顺磁氧化铁纳米微粒 人表皮生长因子受体2 Mice Breast cancer Fluorescence imaging Magnetic resonance imaging Superparamagnetic iron oxide nanoparticles Human epidermal growth factor receptor 2
  • 相关文献

参考文献3

二级参考文献38

  • 1王启俊,祝伟星,邢秀梅.北京城区女性乳腺癌发病死亡和生存情况20年监测分析[J].中华肿瘤杂志,2006,28(3):208-210. 被引量:81
  • 2Jemal A, Bray F, Center MM, et al. Global cancer statistics[ J]. CA Cancer J Clin, 2011, 61 (2) : 69-90.
  • 3Gennari A, Sormani MP, Pronzato P, et al. HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: a pooled analysis of randomized trials [ J ]. J Natl Cancer Inst, 2008, 100 ( 1 ) : 14-20.
  • 4Bartlett JM, Munro AF, Dunn JA, et al. Predictive markers of anthracycline benefit: a prospectively planned analysis of the UK National Epirubicin Adjuvant Trial (NEAT/BR9601) [ J]. Lancet Oncol, 2010, 11 (3) :266-274.
  • 5Gianni L, Dafni U, Gelber RD, et al. Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2- positive early breast cancer: a 4-year follow-up of a randomised controlled trial[ J ]. Lancet Oncol, 2011, 12 ( 3 ) : 236-244.
  • 6Perez EA, Romond EH, Suman VJ, et al. Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31 [J]. J Clin Oncol, 2011, 29(25):3366-3373.
  • 7Slamon D, Eiermann W, Robert N, et al. Adjuvant trastuzumab in HER2-positive breast cancer[ J]. N Engl J Med, 2011, 365( 14 ) : 1273-1283.
  • 8Costa RB, Kurra G, Greenberg L, et al. Efficacy and cardiac safety of adjuvant trastuzumab-based chemotherapy regimens for HER2-positive early breast cancer [ J ]. Ann Oncol, 2010, 21 ( 11 ) :2153-2160.
  • 9Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2 [ J ]. N Engl J Med, 2001, 344 ( 11 ) :783-792.
  • 10Gianni L, Ei W, Serglazov V, et al. Neoadjuvant chemotherapy with trastuzmmb followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer ( the NOAH trial) : a randomised controlled superiority trial with a parallel HER2-negative cohort [J]. Lancet, 2010, 375(9712) :377-384.

共引文献31

同被引文献44

引证文献3

二级引证文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部